{"id":245212,"date":"2026-10-10T21:02:20","date_gmt":"2026-10-11T02:02:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/10\/oncopeptides-confirms-blood-brain-barrier-penetration-based-on-data-from-first-patients-in-glioblastoma-window-of-opportunity-woo-study"},"modified":"2026-10-10T21:02:20","modified_gmt":"2026-10-11T02:02:20","slug":"oncopeptides-confirms-blood-brain-barrier-penetration-based-on-data-from-first-patients-in-glioblastoma-window-of-opportunity-woo-study","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/10\/oncopeptides-confirms-blood-brain-barrier-penetration-based-on-data-from-first-patients-in-glioblastoma-window-of-opportunity-woo-study","title":{"rendered":"Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/oncopeptides-confirms-blood-brain-barrier-penetration-based-on-data-from-first-patients-in-glioblastoma-window-of-opportunity-woo-study2.jpg\"><\/a><\/p>\n<p>Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. Data from the first three treated patients demonstrate successful penetration of the human blood-brain barrier (BBB) with intra-tumoral drug concentrations in line with preclinical models, alongside good tolerability where the first patient has received five monthly doses to date without any major drug-related toxicity.<\/p>\n<p>The blood-brain barrier represents one of the greatest hurdles in neuro-oncology, causing more than 90 percent of conventional systemic cancer drugs to fail because they cannot reach the brain. By confirming meaningful, BBB penetration and delivery of a cytotoxic payload into brain tumor cells in the first patients, the findings provide a strong indication of a clinical proof-of-concept for the PDC platform\u2019s mechanism in solid brain tumors.<\/p>\n<p><em>\u201cReaching our primary objective to confirm that our PDC technology successfully crosses the human blood-brain barrier is a major breakthrough for Oncopeptides,\u201d <\/em>says Sofia Heigis, CEO of Oncopeptides. <em>\u201cFor decades, the blood-brain barrier has locked out effective treatments for glioblastoma patients. Demonstrating meaningful drug penetration in resected brain tumors in patients after a single dose validates the fundamental strength and versatility of our platform, transforming our brain cancer program from an ambitious basic scientific premise into a true, clinically justified, opportunity.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. Data from the first three treated patients demonstrate successful penetration of the human blood-brain barrier (BBB) with intra-tumoral drug [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-245212","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=245212"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245212\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=245212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=245212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=245212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}